Login to Your Account

Ataluren phase III a dud in CF; future dim in other indications

By Marie Powers
News Editor

Thursday, March 2, 2017

The troubled development program for ataluren took another turn for the worse when the phase III Ataluren Confirmatory Trial in nmCF fell short across the board, missing both primary and secondary endpoints.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription